SGMT | Sagimet Biosciences Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.21 - 3.65
52 Week Range	2.3900 - 7.38
Beta	2.33
Implied Volatility	216.10%
IV Rank	23.62%
Day's Volume	505,617
Average Volume	851,274
Shares Outstanding	30,674,854
Market Cap	100,000,024
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-07-17

Valuation
Profitability
Growth
Health
P/E Ratio	-2.25
Forward P/E Ratio	N/A
EPS	-1.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

*Chart delayed

Analyzing fundamentals for SGMT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see SGMT Fundamentals page.

Watching at SGMT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SGMT Technicals page.